Latest news with #RM00.02
Yahoo
30-04-2025
- Business
- Yahoo
Why It Might Not Make Sense To Buy Ornapaper Berhad (KLSE:ORNA) For Its Upcoming Dividend
It looks like Ornapaper Berhad (KLSE:ORNA) is about to go ex-dividend in the next 4 days. The ex-dividend date generally occurs two days before the record date, which is the day on which shareholders need to be on the company's books in order to receive a dividend. The ex-dividend date is important because any transaction on a stock needs to have been settled before the record date in order to be eligible for a dividend. Accordingly, Ornapaper Berhad investors that purchase the stock on or after the 5th of May will not receive the dividend, which will be paid on the 20th of May. The company's next dividend payment will be RM00.02 per share. Last year, in total, the company distributed RM0.02 to shareholders. Looking at the last 12 months of distributions, Ornapaper Berhad has a trailing yield of approximately 2.4% on its current stock price of RM00.84. If you buy this business for its dividend, you should have an idea of whether Ornapaper Berhad's dividend is reliable and sustainable. We need to see whether the dividend is covered by earnings and if it's growing. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. If a company pays out more in dividends than it earned, then the dividend might become unsustainable - hardly an ideal situation. Ornapaper Berhad paid out a comfortable 27% of its profit last year. Yet cash flow is typically more important than profit for assessing dividend sustainability, so we should always check if the company generated enough cash to afford its dividend. Ornapaper Berhad paid a dividend despite reporting negative free cash flow last year. That's typically a bad combination and - if this were more than a one-off - not sustainable. Check out our latest analysis for Ornapaper Berhad Click here to see how much of its profit Ornapaper Berhad paid out over the last 12 months. When earnings decline, dividend companies become much harder to analyse and own safely. If business enters a downturn and the dividend is cut, the company could see its value fall precipitously. Readers will understand then, why we're concerned to see Ornapaper Berhad's earnings per share have dropped 16% a year over the past five years. Ultimately, when earnings per share decline, the size of the pie from which dividends can be paid, shrinks. Another key way to measure a company's dividend prospects is by measuring its historical rate of dividend growth. Ornapaper Berhad's dividend payments per share have declined at 8.8% per year on average over the past 10 years, which is uninspiring. While it's not great that earnings and dividends per share have fallen in recent years, we're encouraged by the fact that management has trimmed the dividend rather than risk over-committing the company in a risky attempt to maintain yields to shareholders. Has Ornapaper Berhad got what it takes to maintain its dividend payments? It's disappointing to see earnings per share declining, and this would ordinarily be enough to discourage us from most dividend stocks, even though Ornapaper Berhad is paying out less than half its income as dividends. However, it's also paying out an uncomfortably high percentage of its cash flow, which makes us wonder just how sustainable the dividend really is. With the way things are shaping up from a dividend perspective, we'd be inclined to steer clear of Ornapaper Berhad. With that in mind though, if the poor dividend characteristics of Ornapaper Berhad don't faze you, it's worth being mindful of the risks involved with this business. Every company has risks, and we've spotted 3 warning signs for Ornapaper Berhad (of which 1 makes us a bit uncomfortable!) you should know about. Generally, we wouldn't recommend just buying the first dividend stock you see. Here's a curated list of interesting stocks that are strong dividend payers. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
23-03-2025
- Business
- Yahoo
Sports Toto Berhad (KLSE:SPTOTO) Stock Goes Ex-Dividend In Just Three Days
Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Sports Toto Berhad (KLSE:SPTOTO) is about to trade ex-dividend in the next three days. Typically, the ex-dividend date is two business days before the record date, which is the date on which a company determines the shareholders eligible to receive a dividend. The ex-dividend date is important as the process of settlement involves at least two full business days. So if you miss that date, you would not show up on the company's books on the record date. Thus, you can purchase Sports Toto Berhad's shares before the 27th of March in order to receive the dividend, which the company will pay on the 18th of April. The company's next dividend payment will be RM00.02 per share. Last year, in total, the company distributed RM0.08 to shareholders. Based on the last year's worth of payments, Sports Toto Berhad has a trailing yield of 5.7% on the current stock price of RM01.41. Dividends are a major contributor to investment returns for long term holders, but only if the dividend continues to be paid. We need to see whether the dividend is covered by earnings and if it's growing. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Dividends are typically paid from company earnings. If a company pays more in dividends than it earned in profit, then the dividend could be unsustainable. Sports Toto Berhad paid out more than half (54%) of its earnings last year, which is a regular payout ratio for most companies. Yet cash flows are even more important than profits for assessing a dividend, so we need to see if the company generated enough cash to pay its distribution. Fortunately, it paid out only 26% of its free cash flow in the past year. It's encouraging to see that the dividend is covered by both profit and cash flow. This generally suggests the dividend is sustainable, as long as earnings don't drop precipitously. View our latest analysis for Sports Toto Berhad Click here to see the company's payout ratio, plus analyst estimates of its future dividends. Companies that aren't growing their earnings can still be valuable, but it is even more important to assess the sustainability of the dividend if it looks like the company will struggle to grow. Investors love dividends, so if earnings fall and the dividend is reduced, expect a stock to be sold off heavily at the same time. With that in mind, we're not enthused to see that Sports Toto Berhad's earnings per share have remained effectively flat over the past five years. We'd take that over an earnings decline any day, but in the long run, the best dividend stocks all grow their earnings per share. The main way most investors will assess a company's dividend prospects is by checking the historical rate of dividend growth. Sports Toto Berhad's dividend payments per share have declined at 7.3% per year on average over the past 10 years, which is uninspiring. Is Sports Toto Berhad worth buying for its dividend? The payout ratios appear reasonably conservative, which implies the dividend may be somewhat sustainable. Still, with earnings basically flat, Sports Toto Berhad doesn't stand out from a dividend perspective. In summary, while it has some positive characteristics, we're not inclined to race out and buy Sports Toto Berhad today. However if you're still interested in Sports Toto Berhad as a potential investment, you should definitely consider some of the risks involved with Sports Toto Berhad. Case in point: We've spotted 2 warning signs for Sports Toto Berhad you should be aware of. Generally, we wouldn't recommend just buying the first dividend stock you see. Here's a curated list of interesting stocks that are strong dividend payers. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
06-03-2025
- Business
- Yahoo
Autocount Dotcom Berhad (KLSE:ADB) Stock Goes Ex-Dividend In Just Four Days
Readers hoping to buy Autocount Dotcom Berhad (KLSE:ADB) for its dividend will need to make their move shortly, as the stock is about to trade ex-dividend. Typically, the ex-dividend date is two business days before the record date, which is the date on which a company determines the shareholders eligible to receive a dividend. The ex-dividend date is an important date to be aware of as any purchase of the stock made on or after this date might mean a late settlement that doesn't show on the record date. Therefore, if you purchase Autocount Dotcom Berhad's shares on or after the 11th of March, you won't be eligible to receive the dividend, when it is paid on the 26th of March. The company's next dividend payment will be RM00.02 per share. Last year, in total, the company distributed RM0.04 to shareholders. Based on the last year's worth of payments, Autocount Dotcom Berhad has a trailing yield of 4.0% on the current stock price of RM01.01. We love seeing companies pay a dividend, but it's also important to be sure that laying the golden eggs isn't going to kill our golden goose! That's why we should always check whether the dividend payments appear sustainable, and if the company is growing. See our latest analysis for Autocount Dotcom Berhad Dividends are usually paid out of company profits, so if a company pays out more than it earned then its dividend is usually at greater risk of being cut. Autocount Dotcom Berhad distributed an unsustainably high 112% of its profit as dividends to shareholders last year. Without extenuating circumstances, we'd consider the dividend at risk of a cut. Yet cash flow is typically more important than profit for assessing dividend sustainability, so we should always check if the company generated enough cash to afford its dividend. Over the last year, it paid out more than three-quarters (85%) of its free cash flow generated, which is fairly high and may be starting to limit reinvestment in the business. It's good to see that while Autocount Dotcom Berhad's dividends were not covered by profits, at least they are affordable from a cash perspective. If executives were to continue paying more in dividends than the company reported in profits, we'd view this as a warning sign. Very few companies are able to sustainably pay dividends larger than their reported earnings. Click here to see how much of its profit Autocount Dotcom Berhad paid out over the last 12 months. Companies with consistently growing earnings per share generally make the best dividend stocks, as they usually find it easier to grow dividends per share. If earnings fall far enough, the company could be forced to cut its dividend. It's encouraging to see Autocount Dotcom Berhad has grown its earnings rapidly, up 31% a year for the past five years. The main way most investors will assess a company's dividend prospects is by checking the historical rate of dividend growth. Autocount Dotcom Berhad's dividend payments are broadly unchanged compared to where they were two years ago. From a dividend perspective, should investors buy or avoid Autocount Dotcom Berhad? Autocount Dotcom Berhad has been growing its earnings per share nicely, although judging by the difference between its profit and cashflow payout ratios, the company might have reported some write-offs over the last year. In summary, while it has some positive characteristics, we're not inclined to race out and buy Autocount Dotcom Berhad today. So if you want to do more digging on Autocount Dotcom Berhad, you'll find it worthwhile knowing the risks that this stock faces. To that end, you should learn about the 3 warning signs we've spotted with Autocount Dotcom Berhad (including 2 which make us uncomfortable). A common investing mistake is buying the first interesting stock you see. Here you can find a full list of high-yield dividend stocks. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
01-03-2025
- Business
- Yahoo
Four Days Left Until Duopharma Biotech Berhad (KLSE:DPHARMA) Trades Ex-Dividend
Duopharma Biotech Berhad (KLSE:DPHARMA) stock is about to trade ex-dividend in 4 days. The ex-dividend date is commonly two business days before the record date, which is the cut-off date for shareholders to be present on the company's books to be eligible for a dividend payment. The ex-dividend date is of consequence because whenever a stock is bought or sold, the trade can take two business days or more to settle. This means that investors who purchase Duopharma Biotech Berhad's shares on or after the 5th of March will not receive the dividend, which will be paid on the 19th of March. The company's next dividend payment will be RM00.02 per share, on the back of last year when the company paid a total of RM0.03 to shareholders. Based on the last year's worth of payments, Duopharma Biotech Berhad stock has a trailing yield of around 2.5% on the current share price of RM01.22. Dividends are an important source of income to many shareholders, but the health of the business is crucial to maintaining those dividends. That's why we should always check whether the dividend payments appear sustainable, and if the company is growing. See our latest analysis for Duopharma Biotech Berhad If a company pays out more in dividends than it earned, then the dividend might become unsustainable - hardly an ideal situation. That's why it's good to see Duopharma Biotech Berhad paying out a modest 46% of its earnings. Yet cash flow is typically more important than profit for assessing dividend sustainability, so we should always check if the company generated enough cash to afford its dividend. Dividends consumed 54% of the company's free cash flow last year, which is within a normal range for most dividend-paying organisations. It's encouraging to see that the dividend is covered by both profit and cash flow. This generally suggests the dividend is sustainable, as long as earnings don't drop precipitously. Click here to see the company's payout ratio, plus analyst estimates of its future dividends. Stocks with flat earnings can still be attractive dividend payers, but it is important to be more conservative with your approach and demand a greater margin for safety when it comes to dividend sustainability. If earnings fall far enough, the company could be forced to cut its dividend. With that in mind, we're not enthused to see that Duopharma Biotech Berhad's earnings per share have remained effectively flat over the past five years. Better than seeing them fall off a cliff, for sure, but the best dividend stocks grow their earnings meaningfully over the long run. Earnings per share growth has been slim, and the company is already paying out a majority of its earnings. While there is some room to both increase the payout ratio and reinvest in the business, generally the higher a payout ratio goes, the lower a company's prospects for future growth. The main way most investors will assess a company's dividend prospects is by checking the historical rate of dividend growth. Duopharma Biotech Berhad's dividend payments per share have declined at 6.6% per year on average over the past 10 years, which is uninspiring. Has Duopharma Biotech Berhad got what it takes to maintain its dividend payments? Earnings per share have been flat over the 10-year timeframe we consider, and Duopharma Biotech Berhad paid out less than half its earnings and more than half its free cashflow over the last year. To summarise, Duopharma Biotech Berhad looks okay on this analysis, although it doesn't appear a stand-out opportunity. With that in mind, a critical part of thorough stock research is being aware of any risks that stock currently faces. Our analysis shows 1 warning sign for Duopharma Biotech Berhad and you should be aware of it before buying any shares. If you're in the market for strong dividend payers, we recommend checking our selection of top dividend stocks. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
28-02-2025
- Business
- Yahoo
Four Days Left Until Duopharma Biotech Berhad (KLSE:DPHARMA) Trades Ex-Dividend
Duopharma Biotech Berhad (KLSE:DPHARMA) stock is about to trade ex-dividend in 4 days. The ex-dividend date is commonly two business days before the record date, which is the cut-off date for shareholders to be present on the company's books to be eligible for a dividend payment. The ex-dividend date is of consequence because whenever a stock is bought or sold, the trade can take two business days or more to settle. This means that investors who purchase Duopharma Biotech Berhad's shares on or after the 5th of March will not receive the dividend, which will be paid on the 19th of March. The company's next dividend payment will be RM00.02 per share, on the back of last year when the company paid a total of RM0.03 to shareholders. Based on the last year's worth of payments, Duopharma Biotech Berhad stock has a trailing yield of around 2.5% on the current share price of RM01.22. Dividends are an important source of income to many shareholders, but the health of the business is crucial to maintaining those dividends. That's why we should always check whether the dividend payments appear sustainable, and if the company is growing. See our latest analysis for Duopharma Biotech Berhad If a company pays out more in dividends than it earned, then the dividend might become unsustainable - hardly an ideal situation. That's why it's good to see Duopharma Biotech Berhad paying out a modest 46% of its earnings. Yet cash flow is typically more important than profit for assessing dividend sustainability, so we should always check if the company generated enough cash to afford its dividend. Dividends consumed 54% of the company's free cash flow last year, which is within a normal range for most dividend-paying organisations. It's encouraging to see that the dividend is covered by both profit and cash flow. This generally suggests the dividend is sustainable, as long as earnings don't drop precipitously. Click here to see the company's payout ratio, plus analyst estimates of its future dividends. Stocks with flat earnings can still be attractive dividend payers, but it is important to be more conservative with your approach and demand a greater margin for safety when it comes to dividend sustainability. If earnings fall far enough, the company could be forced to cut its dividend. With that in mind, we're not enthused to see that Duopharma Biotech Berhad's earnings per share have remained effectively flat over the past five years. Better than seeing them fall off a cliff, for sure, but the best dividend stocks grow their earnings meaningfully over the long run. Earnings per share growth has been slim, and the company is already paying out a majority of its earnings. While there is some room to both increase the payout ratio and reinvest in the business, generally the higher a payout ratio goes, the lower a company's prospects for future growth. The main way most investors will assess a company's dividend prospects is by checking the historical rate of dividend growth. Duopharma Biotech Berhad's dividend payments per share have declined at 6.6% per year on average over the past 10 years, which is uninspiring. Has Duopharma Biotech Berhad got what it takes to maintain its dividend payments? Earnings per share have been flat over the 10-year timeframe we consider, and Duopharma Biotech Berhad paid out less than half its earnings and more than half its free cashflow over the last year. To summarise, Duopharma Biotech Berhad looks okay on this analysis, although it doesn't appear a stand-out opportunity. With that in mind, a critical part of thorough stock research is being aware of any risks that stock currently faces. Our analysis shows 1 warning sign for Duopharma Biotech Berhad and you should be aware of it before buying any shares. If you're in the market for strong dividend payers, we recommend checking our selection of top dividend stocks. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
